 SAN DIEGO, March 25, 2021 GLOBE NEWSWIRE -- Exagen Inc. Nasdaq: XGN, a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters full exercise of their option to purchase additional shares, at a price to the public of 16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately 69.1 million. 